
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
What are the key differences?
Joseph F. Goldberg, MD, shares some key takeaways from “Medical Crossfire: Treatment Approaches to Mixed Features of Bipolar vs Unipolar Depression,” his discussion with Sanjai Rao, MD, of the University of California, San Diego, and Nassir Ghaemi, MD, of Tufts University School of Medicine, at the
Dr Goldberg is a clinical professor of psychiatry at Mount Sinai School of Medicine.





